TRANSTHERA-B(02617) published an exploratory clinical study on the core product Tenofovir alafenamide for the treatment of bile duct cancer.

TRANSTHERA-B (02617) announced that the exploratory phase 2 clinical trial results of its core product, Tengotinib, for cholangiocarcinoma conducted in the United States have been published in "The Lancet Gastroenterology & Hepatology" (impact factor 38.6). Cholangiocarcinoma is an aggressively invasive cancer of the biliary tract system, often driven by FGFR2 fusion mutations, which can be targeted by inhibitors such as pemigatinib and futibatinib. However, resistance often occurs due to the emergence of acquired FGFR2 mutations. In this phase 2, open-label, multicenter study (NCT04919642), eligible cholangiocarcinoma patients included those with FGFR2 fusion who were resistant to FGFR inhibitors either primarily or acquirably, those with other FGFR gene alterations, as well as those with FGFR wild-type. Tengotinib was able to overcome acquired resistance to FGFR inhibitors in FGFR2 fusion-positive cholangiocarcinoma patients and demonstrated anti-tumor activity in cholangiocarcinoma patients with other FGFR gene alterations.